#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: pulmonary arterial hypertension
Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension ...
Sotatercept improves outcomes in patients with pulmonary arterial hypertension
1. Among patients on stable therapy for pulmonary arterial hypertension (PAH), sotatercept resulted in a significant improvement in six-minute walk ...
Sotatercept decreased vascular resistance in pulmonary arterial hypertension
1. Treatment with sotatercept decreased pulmonary vascular resistance in patients with pulmonary arterial hypertension. 2. Sotatercept caused adverse side effects ...
![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://www.2minutemedicine.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-350x250.jpg)
Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]
Image: CC 1. Macitentan, a derivative of the endothelin receptor antagonist bosentan, reduced morbidity from pulmonary arterial hypertension compared to ...
2 Minute Medicine Rewind July 22 – July 28, 2013
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the ...
New genetic link in pulmonary arterial hypertension holds therapeutic promise
Image: PD 1. A new link has been found between KCNK3 gene mutations and pulmonary arterial hypertension. 2. The mutations ...